Chronic effects of platinum(IV) complex and its diamine ligand on rat heart function: comparison with cisplatin
- 6 Downloads
The aim of the present study was to compare the cardiodynamic parameters in the isolated rat heart in animals chronically treated with cisplatin, platinum(IV) complex and its diamine ligand. Sixty Wistar albino rats (8 weeks old) were divided into five groups: three experimental and two control groups. Animals in all groups were treated with a dose of 4 mg/kg body weight once a week for 4 weeks with different substances; experimental groups received cisplatin, ligand and octahedral platinum(IV) complex, and control groups received saline and dimethyl sulfoxide. After sacrificing the animals, hearts were isolated and perfused according to the Langendorff technique at gradually increased coronary perfusion pressures (40–120 cmH2O). The following parameters of cardiac function were continuously recorded: maximum and minimum rate of change of pressure in the left ventricle, systolic and diastolic left ventricular pressure, heart rate and coronary flow. The results showed statistically significant differences between all experimental groups in maximum and minimum rate of pressure development as well as in systolic pressure of the left ventricle, whereas cisplatin, ligand and the platinum(IV) complex had effects on heart contractility without significant influences on coronary circulation. The findings of the present study could be important for a better understanding of anticancer drug cardiac side effects. Our results indicate that compared to cisplatin as a “gold standard”, novel platinum complexes and ligands do not possess fewer negative effects on the heart, indicating insufficient safety for their usage in terms of affecting cardiac function, a result that can be of great interest for further investigations.
KeywordsCisplatin Ligand Platinum(IV) complex Rat Cardiodynamics
This work was supported by the Faculty of Medical Sciences, University of Kragujevac (Junior Project No. 09/2011).
Compliance with ethical standards
Conflicts of interest
None of the authors of the present study has any actual or potential conflicts of interest to disclose, including financial, personal, or other relationships with specific persons or organizations.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Research procedures were carried out in accordance with European Directive for the Welfare of Laboratory Animals (86/609/EEC) and Principles of Good Laboratory Practice (GLP) and approved by the Ethical Committee of the Faculty of Medical Sciences University of Kragujevac, number: 01-4583.
- 4.Misirlic Dencic S, Poljarevic J, Vilimanovich U, Bogdanovic A, Isakovic AJ, Kravic Stevovic T, Dulovic M, Zogovic N, Isakovic AM, Grguric-Sipka S, Bumbasirevic V, Sabo T, Trajkovic V, Markovic I (2012) Cyclohexyl analogues of ethylenediamine dipropanoic acid induce caspase-independent mitochondrial apoptosis in human leukemic cells. Chem Res Toxicol 25:931–939. https://doi.org/10.1021/tx3000329 CrossRefGoogle Scholar
- 20.Rosic G, Selakovic D, Joksimovic J, Srejovic I, Zivkovic V, Tatalović N, Orescanin-Dusic Z, Mitrovic S, Ilic M, Jakovljevic V (2016) The effects of N-acetylcysteine on cisplatin-induced changes of cardiodynamic parameters within coronary autoregulation range in isolated rat hearts. Toxicol Lett 242:34–46. https://doi.org/10.1016/j.toxlet.2015.11.028 CrossRefGoogle Scholar
- 22.Bano N, Najam R, Qazi F (2013) Adverse cardiac manifestations of cisplatin—a review. Int J Pharm Sci Rev Res 18:80–85Google Scholar
- 26.Altena R, Hummel YM, Nuver J, Smit AJ, Lefrandt JD, de Boer RA, Voors AA, van den Berg MP, de Vries EG, Boezen HM, Gietema JA (2011) Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 22:2286–2293. https://doi.org/10.1093/annonc/mdr408 CrossRefGoogle Scholar
- 31.Kaluđerović GN, Đinović VM, Juranić ZD, Stanojković TP, Sabo TJ (2005) Activity of some platinum(II/IV) complexes with O, O-n-butyl-and O, O-n-pentyl-ethylenediamine-N, N’-di-3-propanoate and halogeno ligands against HeLa and K562 cell lines and human PBMC. J Inorg Biochem 99:488–496. https://doi.org/10.1016/j.jinorgbio.2004.10.025 CrossRefGoogle Scholar
- 32.Lazić JM, Vucićević L, Grgurić-Sipka S, Janjetović K, Kaluderović GN, Misirkić M, Gruden-Pavlović M, Popadić D, Paschke R, Trajković V, Sabo TJ (2010) Synthesis and in vitro anticancer activity of octahedral platinum(IV) complexes with cyclohexyl-functionalized ethylenediamine-N, N’-diacetate-type ligands. Chem Med Chem 5:881–889. https://doi.org/10.1002/cmdc.201000058 CrossRefGoogle Scholar
- 33.Jolley JN, Yanovsky AI, Kelland LR, Nolan KB (2001) Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4 Cl2]H2O where L4 is ethylenediamine-N,N0 -diacetate. J Inorg Biochem 83(2–3):91–100. https://doi.org/10.1016/s0162-0134(00)00190-2 CrossRefGoogle Scholar
- 34.Misic MM, Jakovljevic VL, Bugarcic ZD, Zivkovic VI, Srejovic IM, Barudzic NS, Djuric DM, Novokmet SS (2015) Platinum complexes-induced cardiotoxicity of isolated, perfused rat heart: comparison of Pt(II) and Pt(IV) analogues versus cisplatin. Cardiovasc Toxicol 15(3):261–268. https://doi.org/10.1007/s12012-014-9293-8 CrossRefGoogle Scholar
- 36.Carver JR, Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ (2007) ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991–4008. https://doi.org/10.1200/JCO.2007.10.9777 CrossRefGoogle Scholar
- 37.Misirlić Denčić S, Poljarević J, Isakovic AM, Marković I, Sabo TJ, Grgurić-Šipka S (2017) Antileukemic action of novel diamine Pt(II) halogenido complexes: comparison of the representative novel Pt(II) with corresponding Pt(IV) complex. Chem Biol Drug Des 90:262–271. https://doi.org/10.1111/cbdd.12945 CrossRefGoogle Scholar